No Data
Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.
In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.
henan lingrui pharmaceutical plans to acquire Silver Valley Pharmaceuticals for 0.782 billion. Traditional Chinese medicine patch and plaster leading the cross-border pharmaceutical market | Quick reading announcement
①Henan Lingrui Pharmaceutical intends to acquire all the equity of Silver Valley Pharmaceutical for 0.782 billion yuan, entering the market of innovative drugs in chemical medicine. ②According to Mononucleosis Medical Data, Silver Valley Pharmaceutical's sales in 2023 exceeded 0.4 billion yuan, with the top-selling product being Jin'erli, accounting for about 70% of the company's total revenue, and the growth rate of Class 1 new drug Biti Cong quickly. ③If the acquisition of Silver Valley Pharmaceutical proceeds smoothly, the company's previously set stock-based incentive unlocking target may be difficult to achieve or significantly reduced.
henan lingrui pharmaceutical (600285.SH): intends to acquire 100% equity of silver valley pharmaceutical
Gelonghui, on December 4, announced that Henan Lingrui Pharmaceutical (600285.SH) has disclosed that the company intends to use its own funds to acquire 100% of the equity of Yingu Pharmaceutical Co., Ltd. (referred to as "Yingu Pharmaceutical" or "symbol"). The company has signed a "Letter of Intent for Acquisition" with Yingu Holdings Group Co., Ltd. and Mr. Wang Wenjun, and all parties have reached a preliminary cooperation intention on the equity acquisition. The company plans to use its own funds to purchase 100% of the equity of the symbol company. Based on the company's preliminary assessment of the symbol company's business, financial status, and team, its comprehensive valuation is tentatively set at no more than 782.12 million yuan (final amount will depend on a third-party professional).
Henan Lingrui Pharmaceutical (SHSE:600285) Could Easily Take On More Debt
Henan Lingrui Pharmaceutical discloses a stock-based incentive plan Unveiling conditions: average annual double-digit growth in non-GAAP net income | Speed reading announcement
①Henan Lingrui Pharmaceutical has announced a new round of restricted stock incentive plan and employee stock ownership plan, slightly lowering the assessment target compared to the previous incentive plan, but still maintaining a double-digit non-GAAP performance assessment requirement. ②In addition to Henan Lingrui Pharmaceutical, tibet cheezheng tibetan medicine has also previously announced an employee stock ownership plan with higher assessment targets, and the industry expects bone health to be a high-potential category in the out-of-hospital market.
Henan Lingrui Pharmaceutical (600285.SH): Plans to use no more than 2.2 billion yuan of idle self-owned funds for cash management.
Henan Lingrui Pharmaceutical (600285.SH) announced on November 29 that on November 29, 2024, the company held the twelfth meeting of the ninth board of directors and the tenth meeting of the ninth board of supervisors, and approved the "Proposal on Authorizing the Use of Idle Own Funds for Money Management", agreeing to use idle own funds not exceeding RMB 2.2 billion for cash management, with funds within the quota available for rolling use.
Are Robust Financials Driving The Recent Rally In Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Stock?
